Page 63 - Read Online

Page 4 of 4 Kwee et al. Hepatoma Res 2022;8:32 https://dx.doi.org/10.20517/2394-5079.2022.58

Copyright
© The Author(s) 2022.

REFERENCES
1. El-khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-
label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502. DOI PubMed PMC
2. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with
sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52. DOI PubMed
3. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol 2020;6:e204564. DOI
PubMed PMC
4. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for
unresectable hepatocellular carcinoma. J Hepatol 2022;76:862-73. DOI PubMed
5. Lee MS, Ryoo B, Hsu C, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an
open-label, multicentre, phase 1b study. Lancet Oncol 2020;21:808-20. DOI PubMed
6. Zhu AX, Guan Y, Abbas AR, et al. Abstract CT044: genomic correlates of clinical benefits from atezolizumab combined with
bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC). Cancer Res 2020;80:CT044-CT044.
DOI
7. Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination
with bevacizumab in advanced hepatocellular carcinoma. Nat Med 2022;28:1599-611. DOI PubMed
8. Feng Z, Xu F, Liu Y, et al. The immune microenvironment and progression of immunotherapy and combination therapeutic strategies
for hepatocellular carcinoma. Hepatoma Res 2021;7:3. DOI
9. Bonilla CM, McGrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.
Hepatoma Res 2020;6:68. DOI PubMed PMC
10. Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6.
DOI PubMed PMC
11. Peng Y, Wong CC, Yu J. The paradox of immunotherapy in NASH-HCC. Signal Transduct Target Ther 2021;6:228. DOI PubMed
PMC
12. Younossi Z, Stepanova M, Ong JP, et al; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest
growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-755.e3. DOI
PubMed
13. Lindblad KE, Ruiz de Galarreta M, Lujambio A. Tumor-intrinsic mechanisms regulating immune exclusion in liver cancers. Front
Immunol 2021;12:642958. DOI PubMed PMC
14. Murai H, Kodama T, Maesaka K, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune
microenvironment in hepatocellular carcinoma. Hepatology 2022. DOI PubMed